Enginzyme and AGC unveil scalable process for key mRNA ingredient at Berlin Conference

BioNTech maps pivotal oncology milestones for 2026

BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company

Camurus’ Oclaiz NDA resubmission accepted by FDA

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026

Pierre Fabre and Iktos team up to accelerate AI-driven cancer drug discovery

Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target

FDA endorses Relmada’s registrational strategy for bladder cancer therapy

Bristol Myers Squibb reports positive Phase 3 results for Camzyos in adolescents with oHCM

The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo

Merck scores FDA nod for TGT drug Pimicotinib, promising new hope for patients

The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes

Codexis teams up with Axolabs to advance enzymatic RNA manufacturing

The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology

GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy

GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today

FDA nod to first-ever treatment for fatal pediatric Menkes disease